Novus International, Inc. and Resilient Biotics have joined forces in a strategic partnership to develop a groundbreaking feed solution aimed at enhancing immunity health and combating respiratory diseases in swine. This innovative product is anticipated to undergo a three-year development process, including comprehensive testing to ensure its effectiveness in addressing the specific needs of the swine industry.
The collaboration between Novus and Resilient Biotics represents a significant milestone in the quest to optimize pig health and mitigate the economic impact of prevalent respiratory challenges such as porcine reproductive and respiratory syndrome (PRRS) and porcine respiratory disease complex (PRDC). By leveraging their respective expertise and resources, both companies are committed to introducing a novel feed solution that promises to revolutionize the swine industry.
Gaurav Shah, Novus’ Associate Director of Innovation and Business Development, highlighted the pressing need for innovative approaches to enhance pig health and minimize the occurrence of respiratory illnesses. He emphasized the potential of the partnership with Resilient Biotics to introduce a game-changing product that could significantly benefit the swine industry.
Resilient Biotics, a leading biotechnology company based in North Carolina, specializes in pioneering microbiome-based strategies to improve animal health. Through this partnership, Resilient Biotics will harness its advanced microbiome product discovery platform and extensive knowledge of swine microbiota to develop tailored solutions that target respiratory health challenges in pigs.
Chris Belnap, CEO and Co-founder of Resilient Biotics, expressed enthusiasm about collaborating with Novus to introduce innovative microbial solutions to the market. He emphasized the importance of leveraging Resilient Biotics’ expertise in swine respiratory microbiome research to identify proprietary microbial strains that can enhance host health and bolster immunity against respiratory pathogens.
Both Novus and Resilient Biotics are committed to delivering a product that offers consistent and measurable benefits to the swine industry. With a focus on scientific rigor and efficacy, the companies are dedicated to conducting thorough testing and research over the course of the three-year development period to ensure the product’s reliability and impact.
This partnership aligns with Novus’ overarching vision to address real-world challenges faced by its customers and enable animals to achieve their full potential. In addition to collaborating with Resilient Biotics, Novus is actively engaged in other product development initiatives, including a partnership with Ginkgo Bioworks to develop enzyme solutions and the acquisition of BioResource International, Inc. in 2024 to enhance its CIBENZA® Enzyme Feed Additive product line.
Dan Meagher, President and CEO of Novus, underscored the company’s commitment to innovation and technology-driven solutions that contribute to the sustainability and efficiency of the animal agriculture industry. By leveraging scientific advancements and cutting-edge technologies, Novus aims to empower meat, milk, and egg producers to meet the growing demands of the market while optimizing resource utilization and animal welfare.
In conclusion, the partnership between Novus International, Inc. and Resilient Biotics represents a significant step towards addressing critical health challenges in the swine industry through innovative feed solutions. With a shared commitment to excellence and sustainability, both companies are poised to revolutionize swine nutrition and health management practices for the benefit of farmers, consumers, and the industry as a whole.
